- PR Newswire•14 days agoaTyr Pharma Presents Additional Data for Resolaris™ Phase 1b/2 Trial in Adult Patients with Facioscapulohumeral Muscular Dystrophy at the 21st International Annual Congress of the World Muscle Society
SAN DIEGO, Oct. 6, 2016 /PRNewswire/ -- aTyr Pharma, Inc. (LIFE), today announced that additional clinical data from aTyr's Phase 1b/2 Trial (002) in adult patients with FSHD were presented at the 21st International Congress of the World Muscle Society in Granada, Spain. "In today's presentation we have provided additional data analyses which reaffirm encouraging trends in two meaningful clinical assessments from our adult FSHD (002) trial," commented John Mendlein, PhD, CEO of aTyr Pharma. Today's presentation includes additional detailed data from the adult FSHD (002) trial covering safety, tolerability, PK, and clinical assessments.
- Investopedia•21 days ago
When scientists and research experts meet in Grenada, Spain, next month, aTyr Pharma will present research on adult patients with muscular dystrophy.
aTyr Pharma Inc. (LIFE)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||2.90 x 600|
|Ask||2.95 x 900|
|Day's Range||2.80 - 2.95|
|52wk Range||2.48 - 13.26|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-1.16|
|Avg Vol (3m)||221,758|
|Dividend & Yield||N/A (N/A)|